Lisavanbulin Uses, Dosage, Side Effects and more
Lisavanbulin is under investigation in clinical trial NCT02895360 (Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma).
| Trade Name | Lisavanbulin |
| Generic | Lisavanbulin |
| Lisavanbulin Other Names | Lisavanbulin |
| Type | |
| Formula | C26H29N9O3 |
| Weight | Average: 515.578 Monoisotopic: 515.23933583 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
